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ABSTRACT:
Multiple myeloma (MM) cells induce relevant angiogenic effects within the human 
bone marrow milieu (huBMM) by the aberrant expression of angiogenic factors. 
Hypoxia triggers angiogenic events within the huBMM and the transcription factor 
hypoxia-inducible factor-1α (HIF-1α) is over-expressed by MM cells. Since synthetic 
miR-199a-5p mimics negatively regulates HIF-1α, we here investigated a miRNA-
based therapeutic strategy against hypoxic MM cells. We indeed found that enforced 
expression of miR-199a-5p led to down-modulated expression of HIF-1α as well as 
of other pro-angiogenic factors such as VEGF-A, IL-8, and FGFb in hypoxic MM cells 
in vitro. Moreover, miR-199a-5p negatively affected MM cells migration, while it 
increased the adhesion of MM cells to bone marrow stromal cells (BMSCs) in hypoxic 
conditions. Furthermore, transfection of MM cells with miR-199a-5p significantly 
impaired also endothelial cells migration and down-regulated the expression of 
endothelial adhesion molecules such as VCAM-1 and ICAM-1. Finally, we identified a 
hypoxia\AKT/miR-199a-5p loop as a potential molecular mechanism responsible of 
miR-199a-5p down-regulation in hypoxic MM cells. Taken together our results indicate 
that miR-199a-5p has an important role for the pathogenesis of MM and support the 
hypothesis that targeting angiogenesis via a miRNA/HIF-1α pathway may represent 
a novel potential therapeutical approach for this still lethal disease.
INTRODUCTION
Multiple myeloma (MM) is characterized by 
abnormal proliferation of malignant plasma cells (PCs) 
within the bone marrow (BM), which leads to paraprotein 
release in the serum, osteolytic bone disease, anemia and 
renal failure [1]. Despite in the recent years important 
achievements in the understanding of MM pathogenesis 
have been obtained [2] and novel research platforms 
[3-5] and new therapeutics [6, 7] have been made 
available, MM invariably progresses to a lethal stage 
and is still an incurable malignancy. Disease progression 
is sustained by a supportive network which is based on 
complex cross-talks and involves a variety of cells of 
the human bone marrow milieu (huBMM), including 
endothelial, inflammatory and stromal cells. In this 
context, the BM angiogenesis plays a critical role in the 
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MM pathogenesis and progression [8] and MM has been 
the first hematological disease in which the prognostic 
relevance of angiogenesis has been demonstrated [9, 10]. 
Interestingly, several studies indicate that monoclonal 
gammopathy of undetermined significance (MGUS) and 
non-active MM (smoldering MM) represent the avascular 
phase of PC malignancies, while active intramedullary 
MM is the vascular phase of the disease. In line with these 
data, increased BM micro-vessel density (BM-MVD) was 
observed in patients with active MM and was correlated 
to disease progression, adverse outcome and resistance 
to chemotherapy [11]. MM cells promote the angiogenic 
switch through the direct expression of angiogenic 
molecules or their induction in the BM stromal cells 
(BMSCs) within the huBMM [12]. In fact, BMSCs may 
cooperate with malignant PCs to produce pro-angiogenic 
factors, which finally induce full angiogenic events. In this 
contest, a critical role in the regulation of the angiogenic 
switch is played by the hypoxic huBMM: in fact, it is now 
becoming clear that MM cells are chronically exposed 
to low oxygen levels and abnormally activate hypoxia-
inducible factors (HIFs) [11, 13]. The aberrant HIFs 
activation in turn increases the BM angiogenesis via up-
regulation of VEGF-A, IL8 and CXCL12 [14]. In addition, 
the hypoxia supports MM cells survival invasion, also 
contributing to disease progression and development of 
drug-resistance [15, 16]. 
Notably, HIF-1α suppression in myeloma cells 
blocks tumoral growth in vivo and interferes negatively 
with angiogenesis and bone destruction [17].
Recent findings have highlighted a relevant role for 
microRNAs (miRNAs) in the regulation of angiogenic 
events [18, 19]. miRNAs are short non-coding RNA 
molecules able to regulate gene expression, affecting 
the stability and/or translation of target mRNAs [20]. In 
MM, specific miRNA signatures have been associated to 
different steps of MM development from normal PCs via 
MGUS to clinically overt MM [21, 22]. Therefore a strong 
relationship between deregulated expression of miRNAs 
and the tumor phenotype has been demonstrated [21-26] 
and miRNA deregulation has been associated to the typical 
chromosomal aberrations [21, 22, 27, 28]. More recently, 
miRNAs beyond their key role in MM pathogenesis, are 
emerging as potential tools for the targeting the miRNA 
network as a novel therapeutic strategy providing a novel 
rationale and a new venue of investigation in this disease 
[29-37]. There is now strong evidence that hypoxia 
controls miRNAs expression in cancer [38-40]; in turn, 
hypoxia-regulated miRNAs interfere with a large variety 
of processes such as angiogenesis, apoptosis, proliferation 
and migration [39]. Among miRNAs deregulated in MM, 
miR-199a-5p is of relevant interest because directly 
targets HIF1-α, a prominent transcription factor which 
regulates angiogenesis, predominantly via induction of 
VEGF transcription [41-43]. Furthermore, it has been 
demonstrated that hypoxia induces down-regulation of 
miR-199a-5p, probably through activation of the AKT 
pathway [44, 45].
On these premises, we investigated the functional 
role of miR-199-5p in MM. We first evaluated its 
expression in a panel of MM cell lines and then we 
studied the biological effect induced in vitro by enforced 
expression of synthetic miR-199a-5p mimics in both 
normoxic and hypoxic conditions. Moreover, we studied 
the anti-tumor potential of in vivo delivered of miR-199a-
5p against human MM xenografts in mice. We believe 
that our results disclose a relevant role of miR-199a-5p in 
MM-angiogenesis and provide the rationale for the design 
of innovative miRNA-based therapeutic approach in this 
disease.
RESULTS
miR-199a-5p expression in human MM cell lines 
and hypoxic-response of MM cells
We first evaluated the miR-199a expression profile 
in a set of MM cell lines (OPM2, U266, KMS11, MM1S, 
RPMI 8266, KMS34, INA6, KMS-12M, NCI-H929, 
SKMM1) as compared to normal BM-derived CD138+ 
PCs from healthy donors.
Among cell lines analyzed by qRT-PCR, we 
found that miR-199a-5p is significantly down-regulated 
in 4 (OPM2, U266, KMS11, MM1S) out of 10 lines as 
compared to normal PCs (Fig. 1A).
To study the response of MM cells to hypoxia, we 
reproduced an hypoxic condition by the use of cobalt 
chloride or by culturing cells for at least 24 hours in a 1% 
O2 atmosphere. By western blotting analysis of nuclear-
enriched extracts from CoCl2-stimulated MM cells, we 
found that hypoxic conditions triggered the increase of 
HIF-1α levels in MM cells (Fig.1B). Similar results were 
obtained when MM cells were cultured in a hypoxia 
chamber (data not shown).
In parallel, we analyzed the expression of miR-
199a-5p in response to hypoxia in MM cells. To this end, 
we used MM cell lines with different basal levels of miR-
199a-5p in standard conditions. We observed a significant 
decrease of miR-199a-5p expression in hypoxic MM cells 
as compared to normoxic counterpart (Fig. 1C). Notably, 
miR-199a-5p expression was further decreased  when 
MM cells where co-cultured with hypoxic BMSCs (Fig. 
1D). These results indicate that hypoxia in MM cells 
down-regulate miR-199a-5p and this effect is further 
strengthened by an hypoxic huBMM.
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miR-199a-5p targets and suppresses HIF-1α 
expression into hypoxic MM cells 
To assess whether miR-199a-5p directly affects 
the expression of HIF-1-α in MM cells, we evaluated 
the effect induced by enforced expression of synthetic 
miR-199a-5p mimics on HIF-1-α protein levels in cells 
exposed to hypoxic culture conditions. By qRT–PCR, we 
first measured the transfection efficiency of miR-199a-5p 
24h after treatment (Supplemental Figure 1A). Notably, 
we observed that enforced expression of miR199a-5p into 
hypoxic MM cells strongly suppressed nuclear HIF-1α 
protein expression (Fig. 2A). 
To validate this interaction in MM cells, OPM2 were 
co-transfected with synthetic miR- 199a-5p or scrambled 
oligonucleotides (NC), together with an expression vector 
carrying the 3’UTR of HIF-1α mRNA cloned downstream 
to the luciferase reporter gene. Figure 2B clearly shows 
a significantly lower luciferase activity in OPM2 cells 
transfected with miR-199a-5p mimics as compared to the 
control. 
Moreover, we investigated the effect induced on 
the mammalian class-III protein deacetylase of the sirtuin 
family (Sirt1), a putative target of miR-199a-5p which 
plays an important role in stabilizing HIF-1α. As shown 
in Fig. 2C, miR-199a-5p indeed reduced Sirt1 protein 
expression. 
miR-199a-5p inhibits the hypoxic induction of 
pro-angiogenic factors and reduces endothelial 
cells migration
qRT-PCR basal analysis of hypoxic MM cells 
revealed that VEGF-A and IL-8 mRNA expression were 
about 8 and 10-fold higher as compared to normoxic cells 
(Supplemental Fig. 2A). Moreover, we found that mRNA 
basic-fibroblast growth factor-2 (bFGF) expression was 
approximately 5-fold higher in hypoxic as compared to 
normoxic cells (Supplemental Fig. 2A). On the basis of 
these findings, we attempted to restore the miR-199a-5p 
expression in MM cells in order to evaluate its activity 
on the expression of pro-angiogenic factors. We indeed 
Figure 1:miR-199a-5p expression in myeloma cells and hypoxic-effect on miR-199a-5p expression in MM cells. (a) 
Quantitative RT-PCR analysis of miR-199a-5p using total RNA from 10 MM cell lines and 1 MM patient sample. Raw Ct values were 
normalized to RNU44 housekeeping snoRNA and expressed as fold increase over control CD138+ cells (black column, 1 arbitrary unit). 
Columns, means; Bars, S.D Values represent mean of three different experiments. (b) Western blotting analysis showing HIF-1α expression 
in nuclear (N) and cytoplasmic (C) -enriched cell fractions of MM cell lines treated for 4 hours with 100µM\L of the hypoxia-mimicking 
Cobalte Chloride. Histone H3 was used as loading control to discriminate the different cell fractions. (c) Quantitative RT-PCR of miR-
199a-5p in OPM2, NCI-H929 and RPMI-8226 MM cell lines cultured in both normoxic and hypoxic conditions. Raw Ct were normalized 
to RNU44 housekeeping snoRNA and expressed as fold increase over normoxic MM cells (black column, 1 arbitrary unit). Columns, 
means; Bars, S.D. Values represent mean of three different experiments. P values were obtained using two-tailed t test.  P<0,05; °P<0,01 (d) 
Quantitative RT–PCR of miR-199a-5p in OPM2 cells co-cultured for 24 hours with BMSCs and then immunopurified by immunomagnetic 
sorting with anti-CD138 beads. Raw Ct values were normalized to RNU44 housekeeping snoRNA and expressed as fold increase over 
normoxic OPM2 cells (black column, 1 arbitrary unit). Columns, means; Bars, S.D. Values represent mean of three different experiments. 
°P<0,01.
Oncotarget4www.impactjournals.com/oncotarget
Figure 3: miR-199a-5p inhibits the hypoxia-induction of pro-angiogenic factors and reduces endothelial cells 
migration. (a) Quantitative RT-PCR of VEGF-A, IL-8 and b-FGF in both normoxic and hypoxic OPM2 cells transfected with synthetic 
miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC). Raw Ct were normalized to b-actin housekeeping and expressed as 
fold increase of negative control (black column, 1 arbitrary unit). Columns, means; Bars, S.D. Values represent mean of three different 
experiments. °P<0,01;  P<0,05. (b) Vascular endothelial growth factor (VEGF-A) protein production in the conditioned medium derived 
from hypoxic OPM2 cells transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC) was determined by 
enzyme-linked immunoadsorbent assay (ELISA). Data presented are the mean of three separate experiments. P<0,05. (c) Chemotaxis assay 
of endothelial cells (HUVEC) exposed to conditioned medium from OPM2 cells transfected with either scrambled (miR-NC) or synthetic 
pre-miR-199a-5p (miR-199a-5p) (right panel); Huvec cells treated as in (c) and observed at contrast phase microscopy (left panel). P<0,05. 
(d) Quantitative RT-PCR of VEGF-A, VCAM1, ICAM1 and IL-8 in Huvec cells exposed for 24 hours to conditioned medium from OPM2 
cells transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC). Raw Ct were normalized to b-actin 
housekeeping and expressed as fold increase of negative control (black column, 1 arbitrary unit). Columns, means; Bars, S.D. Values 
represent mean of three different experiments.  P<0,05.
Figure 2:miR-199a-5p targets HIF-1α and reduces 
HIF-1α and SIRT1 protein expression in hypoxic 
MM cells. (a) Western blotting analysis of HIF-1α 24 hours 
after transfection with synthetic miR-199a-5p (miR-199a-5p) or 
scrambled oligonucleotides (NC) in U266 and OPM2 cell lines 
treated for 4 hours with 100µM\L of the hypoxia-mimicking 
Cobalte Chloride. Tubulin was used as loading control. (b) 
Dual luciferase assay of OPM2 cells co-transfected with firefly 
luciferase constructs containing the 3’UTR of HIF-1α and miR-
199a-5p or scrambled oligonucleotides (NC) as indicated. The 
firefly luciferase activity was normalized to renilla luciferase 
activity. The data are shown as relative luciferase activity of miR-
199a-5p-transfected cells as compared to the control (NC) of a 
total of six experiments from three independent transfections. 
P<0,05. (c) Western blotting analysis of SIRT1 24 hours after 
transfection with synthetic miR-199a-5p (miR-199a-5p) or 
scrambled oligonucleotides (NC) in U266 and OPM2 cell lines 
treated for 4 hours with 100µM\L of the hypoxia-mimicking 
Cobalte Chloride. Tubulin was used as loading control.
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found that enforced expression of miR199a-5p mimics 
significantly reduced VEGF-A, IL-8 and bFGF mRNA, 
both in normoxic as well as in hypoxic cells (Fig. 3A). 
Taking in account that secretion is increased in hypoxic 
MM cells, we investigated whether enforced expression 
of miR-199a-5p in hypoxic MM cells was able to reduce 
VEGF-A protein secretion. Figure 3B shows that miR-
199a-5p transfection in myeloma cells significantly 
decreased VEGF-a protein secretion
To investigate the role of miR-199a-5p in endothelial 
cells migration, we performed a chemotaxis assay. We 
observed that miR-199a-5p mimics produced a relevant 
decrease in the number of endothelial migrating cells 
in normoxic condition (Fig. 3C). Furthermore, addition 
of normoxic conditioned medium from MM cells over-
expressing miR-199a-5p to the endothelial monolayer 
reduced the expression of cell-cell adhesion molecules 
such as VCAM-1 and ICAM-1 (Fig. 3D). Accordingly, 
the expression of VEGF-A and IL-8 mRNA produced 
by endothelial cells, were also significantly decreased 
(Fig.3D).
Taken together, these results indicate that miR-199a-
5p directly inhibits the synthesis of angiogenic factors by 
MM cells and interferes with the MM/endothelial cell 
loop which promotes the basic events in the angiogenic 
response.
miR-199a-5p regulates DDR1 expression and 
decreases chemotaxis of MM cells
The discoidin domain receptor-1 (DDR1) is 
a predicted target of miR-199a-5p [41]. Here we 
investigated if its expression was regulated by miR-199a-
5p in MM cells. We analyzed DDR1 expression in both 
normoxic and hypoxic MM cells transfected with miR-
199a-5p. Western blot analysis demonstrated a strong 
reduction of DDR1 expression in hypoxic MM cells 
(Fig. 4A). qRT-PCR basal analysis of hypoxic MM cells 
revealed that MMP2 mRNA expression was about 5-fold 
higher as compared to normoxic cells (Supplemental Fig. 
2B). Conversely, we found a decrease in metalloproteinase 
MMP2 also, at mRNA and protein level, both in normoxic 
and hypoxic MM cells transfected with miR-199a-5p, 
although these latter effects were mainly detectable in 
hypoxic conditions (Fig. 4A-B).
To assess the effect of miR-199a-5p expression on 
the migration of MM cells, we performed a chemotaxis 
assay on hypoxic and normoxic MM cells. Figure 
4C shows that miR-199a-5p transfection reduces the 
percentage of MM migrating cells both in normoxic and 
in hypoxic conditions.
Figure 4:miR-199a-5p regulates DDR1 expression and decreases migration of MM cells. (a) Western blotting analysis 
of DDR1 and MMP2 24 hours after transfection with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC) in 
OPM2 cells treated for 4 hours with 100µM\L of the hypoxia-mimicking Cobalte Chloride. Tubulin was used as loading control.  P<0,05. 
(b) Quantitative RT-PCR of matrix metalloproteinase-2 (MMP2) in both normoxic and hypoxic OPM2 cells transfected with synthetic 
miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC). Raw Ct were normalized to b-actin housekeeping and expressed as 
fold increase of negative control (black column, 1 arbitrary unit). Columns, means; Bars, S.D. Values represent mean of three different 
experiments. (c) Chemotaxis assay of both normoxic and hypoxic OPM2 cells transfected with synthetic miR-199a-5p (miR-199a-5p) or 
scrambled oligonucleotides (NC). °P0,01.;  P<0,05.
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miR-199a-5p induces adhesion to hypoxic BMSCs 
In order to investigate the role of miR-199a-5p in 
the adhesion of MM cells to BMSCs, we first found that 
hypoxia reduces the adhesion of MM cells to a BMSCs 
monolayer (Supplemental Fig. 3A). Conversely, we 
showed that the enforced expression of miR-199a-5p 
reconstituted the adhesion capacity of hypoxic MM cells 
to a monolayer of hypoxic BMSCs (Fig.5A). Moreover, 
hypoxic MM cells transfected with miR-199a-5p 
expressed higher levels of E-cadherin and lower levels of 
Snail mRNA (Fig.5B-C). Supplemental figure 3B shows 
that the expression of CXCR4 mRNA was increased 
in hypoxic MM cells, while mR-199a-5p transfection 
decreased CXCR4 mRNA levels (Fig. 5D) . In addition, 
BMSCs exposed to conditioned medium of miR-199a-
5p-transfected MM cells showed impaired expression of 
IL6 and IL8. Taken together these findings demonstrate 
that miR199a-5p is able to reverse the invasive phenotype 
induced by hypoxic BM microenvironment.
miR-199a-5p decreases cell proliferation and 
increases apoptosis in hypoxic conditions
To evaluate the effects induced by enforced 
expression of miR-199a-5p on MM cell growth, we 
analyzed cell proliferation, cell cycle and apoptosis. As 
shown in Figure 6A, enforced expression of miR199a-
5p decreased cell growth in all MM cell lines analyzed; 
in particular, cell growth inhibition was more evident 
72 hours after transfection. Cell-cycle analysis showed 
that miR-199a-5p induced only a slight increase in G1 
and a decrease in S-G2 phases under hypoxic conditions 
(Data not shown). Notably, we found up-regulation of 
the cell-cycle inhibitors p21Cip-1 and p27kip-1, even if this 
effect occurred only in hypoxic MM cells (Fig. 6B). 
Figure5: miR-199a-5p overexpression increases adhesion of MM cells to a monolayer of BMSCs under hypoxic 
conditions. (a) Adhesion assay of hypoxic OPM2 cells transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides 
(NC) and seeded on to hypoxic BMSCs monolayer (right panel); OPM2 cells treated as in (a) and observed at contrast phase microscopy 
(left panel)  P<0,05. (b) Western blotting analysis of E-cadherin 24 hours after transfection with synthetic miR-199a-5p (miR-199a-5p) or 
scrambled oligonucleotides (NC) in hypoxia-induced OPM2 cells. Tubulin was used as loading control. (c) Quantitative RT-PCR of Snail in 
both normoxic and hypoxic OPM2 cells transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC). Raw 
Ct were normalized to b-actin housekeeping and expressed as fold increase of negative control (black column, 1 arbitrary unit). Columns, 
means; Bars, S.D. Values represent mean of three different experiments. P<0,05. (d) Quantitative RT-PCR of CXCR4 in both normoxic and 
hypoxic OPM2 cells transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC). Raw Ct were normalized 
to b-actin housekeeping and expressed as fold increase of negative control (black column, 1 arbitrary unit). Columns, means; Bars, S.D. 
Values represent mean of three different experiments.  P<0,05. (e) Quantitative RT-PCR of IL6 and IL8 in normoxic HS5 cells exposed 
for 24 hours to conditioned medium from hypoxic OPM2 cells transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled 
oligonucleotides (NC). Raw Ct were normalized to b-actin housekeeping and expressed as fold increase of negative control (black column, 
1 arbitrary unit). Columns, means; Bars, S.D. Values represent mean of three different experiments.  P<0,05.
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Furthermore, flow cytometry demonstrated that miR-
199a-5p induced apoptosis only in hypoxic MM cells 
(Fig. 6C). Western blot analysis revealed that miR-
199a-5p-induced apoptosis was associated to activation 
of pro-apoptotic proteins caspase 3\7 and cleaved poly 
ADP-ribose polymerase (PARP), as well as reduction of 
the anti-apoptotic BCL-2 protein (Fig. 6D). All together 
these findings provide evidence that enforced expression 
of miR-199a-5p exert antitumor activity in conditions that 
recapitulate the MM hypoxic huBMM .
AKT pathway regulates miR-199a-5p activity in 
hypoxia
To investigate the molecular mechanism of miR-
199a-5p down-regulation in hypoxic MM cells, we 
over-expressed AKT1 in MM cells and we evaluated 
for the miR-199a-5p expression. As shown in Fig. 7A, 
over-expression of AKT1 induced down-regulation of 
miR-199a-5p. Furthermore, when MM cells were treated 
with the PI3-K\AKT inhibitor LY294002, we observed 
restoration of miR-199a-5p expression (Fig.7B). In 
addition, we silenced transiently AKT1 in MM cells and 
we found an increase of miR-199a-5p expression (Fig. 
7C). Interestingly, after miR-199a-5p transfection in MM 
cells, we found a reduction of total and phosphorylated 
AKT1 protein levels (Fig. 7D). These data indicate the 
occurrence of a negative feedback loop between miR-
199a-5p and AKT pathway where miR-199a-5p negatively 
regulates AKT expression, while activation and functional 
AKT represses miR-199a-5p expression (Supplemental 
Fig. 4A).
Another mechanism that control the expression of 
miR-199a is the methylation status of its promoters on 
both Chr1 and Chr19 [42, 46]. To investigate possible 
epigenetic mechanisms involved in the down-modulated 
expression of miR-199a-5p, we treated MM cells with the 
DNA demethylating agent 5-aza-dC [47]. This experiment 
was performed in three different cell lines expressing 
different levels of miR199a-5p and we found that miR-
199a-5p expression was increased only in the two cell 
lines where its levels are low (Supplemental Figure 5A). 
In contrast, no differences were observed in cells where 
Figure6: miR-199a-5p overexpression reduces proliferation and promotes apoptosis in hypoxic MM cells. (a) Cell growth 
curves of OPM2 and U266 transfected with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC). Averaged values 
of three independent experiments are plotted including ±S.D.  P<0,05. (b) Western blotting analysis of p21Cip-1 and p27Kip-1 24 hours after 
transfection with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC) in both normoxic and hypoxia-induced OPM2 
cells. Tubulin was used as loading control. (c) Annexin V-staining of OPM2 cells 48 hours after transfection with synthetic miR-199a-5p 
or scrambled oligonucleotides (NC). The percentage of Annexin-V-positive cells is reported. Data are the average of three independent 
experiments ±S.D. °P<0,01. (d) Western blotting analysis of proteins caspase 3\7, cleaved poly ADP-ribose polymerase (PARP) and Bcl2, 
24 hours after transfection with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC) in both normoxic and hypoxia-
induced OPM2 cells. Tubulin was used as loading control.
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Figure 7: AKT control of miR-199a-5p expression in hypoxic MM cells and involvement of DNA methylation in down-
regulation of miR-199a-5p in multiple myeloma cells. (a) NCI-H929 cells were electroporated with the pcDNA.3.1-HA-myr-AKT 
dominant active construct (AKT) or the empty vector pcDNA3.1 (vector) and 48 hours later analyzed for miR-199a-5p expression levels by 
quantitative RT–PCR. Raw Ct values were normalized to RNU44 housekeeping snoRNA and expressed as fold increase over vector (black 
column, 1 arbitrary unit). Columns, means; Bars, S.D Values represent mean of three different experiments. °P<0,01. (b) Quantitative RT–
PCR of miR-199a-5p in NCI-H929 cells treated with 20 µM LY294002 or vehicle (DMSO) for 48 hours. Raw Ct values were normalized 
to RNU44 housekeeping snoRNA and expressed as fold increase over vehicle (black column, 1 arbitrary unit). Columns, means; Bars, S.D 
Values represent mean of three different experiments.  P<0,05. (c) NCI-H929 cells were electroporated with an AKT short hairpin (sh)
RNA- or control (SCR) shRNA plasmids and 48 hours later analyzed for miR-199a-5p expression levels by quantitative RT–PCR. Raw Ct 
values were normalized to RNU44 housekeeping snoRNA and expressed as fold increase over control (SCR) (black column, 1 arbitrary 
unit). Columns, means; Bars, S.D Values represent mean of three different experiments.  P<0,05. (d) Western blotting analysis of total and 
phospho-AKT 24 hours after transfection with synthetic miR-199a-5p (miR-199a-5p) or scrambled oligonucleotides (NC) in OPM2 cells 
treated for 4 hours with 100µM\L of the hypoxia-mimicking Cobalte Chloride. Tubulin was used as loading control.
Figure 8: In vivo anti-tumor activity of miR-199a-5p after intratumoral delivery in MM mouse-models. (a) In vivo 
tumor growth of NCI-H929 xenografts intratumorally-treated with NLE (MaxSuppressorTM In Vivo RNA-Lancer II)-miR-199a-5p or miR-
NC. Palpable subcutaneous tumor xenografts were treated every 3 days (indicated by arrows) for a total of six injections, with 20 µg of 
formulated miR-199a-5p or miR-NC. Tumors were measured with an electronic caliper every two days, averaged tumor volume of each 
group ±S.D. are shown.  P<0,05. (b) Survival curves (Kaplan-Meier) of intratumorally miR-199a-5p treated mices show prolongation of 
survival compared to miR-NC (log-rank test, P=0.023). Survival was evaluated from the first day of treatment until death or sacrifice. 
Percent of mice alive is shown.
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miR199a-5p is not down-regulated. 
In order to clarify if down-regulation of miR-
199a-5p in MM cell lines specifically depend by 
hypermethylation of its two promoter regions in 
chromosome 19 (1a) and in chromosome 1 (2a), 
respectively, the methylation levels of CpG sites located 
within these regions were evaluated by Sequenom 
MassARRAY EpiTYPER. To this aim, OPM2, U266 and 
NCI-H929 MM cells were treated with 1μM 5-azacytidine 
or with vehicle (RPMI medium) [36].
We observed that the methylation status of the 
promoter regions remained basically unchanged, 
(Supplemental Fig. 5B) despite that the azacytidine 
treatment increased miR-199a-5p levels in OPM2 and 
U266 MM cells (data not shown).
In order to further verify if the demethylation of 
miR-199a promoters was dose-dependent, we treated 
U266 cell line with either 5μM 5-azacytidine or with 
trichostatin A, a histone deacetylase inhibitor with 
demethylating activity. Again we did not observe 
demethylation of miR-199a-5p (Supplemental Fig. 5C) of 
both promoter regions.
These results suggest that the increase of miR-199a-
5p expression following treatment with 5-AZA does not 
involve the de-methylation of mir199a-5p promoters thus 
suggesting an alternative as yet unidentified epigenetic 
mechanism. 
In vivo anti-tumor activity of formulated miR-
199a-5p against MM xenografts 
We next investigated the effect of miR-199a-5p 
treatment on MM xenograft growth in NOD-SCID mice. 
miR-199a-5p or miR-NC were administered with NLE 
particles, a formulation specifically designed for the 
delivery of oligonucleotides in vivo. A highly significant 
( P<0,05) inhibition of tumor growth was detected 
following 6 injections (3 days apart) of miR-199a-5p 
formulated in NLE particles in NCI-H929 xenografts 
(Fig. 8A). Furthermore, we observed a prolongation of 
survival (P=0.02) of mice treated with miR-199a-5p 
mimics compared to control groups (median survival was 
29 days versus 20 days in the control group) (Fig. 8B). 
We therefore conclude that miR-199a-5p by intratumoral 
delivery is highly effective against MM xenografts and 
significantly prolongs host survival.
DISCUSSION
MM growth and progression is characterized by 
relevant angiogenic events that occur within the huBBM 
chronically exposed to low oxygen levels [11, 48, 49]. The 
BM hypoxia triggers the expression of a variety of genes 
essential for adaptation, cell invasion, dissemination and 
drug-resistance of MM cells [50]. Indeed, the hypoxia 
inducible-factor 1-α (HIF-1α), the master regulator of 
cellular response to hypoxia, is known to be abnormally 
activated in the BM of MM patients. Aberrant HIF1-α 
activation in MM cells contributes to the pathogenesis 
of the disease increasing angiogenesis via up-regulation 
of IL-8 and VEGF-A [8]. In this scenario, a variety of 
miRNAs have been found to play a relevant role as 
regulators of huBMM angiogenic events [51-53].
Here, we focused on the role of miR-199a-5p in 
both normoxic and hypoxic MM cells, because HIF-1α 
is predicted to be a potential target of miR-199a-5p [54]. 
It has been reported that miR-199a-5p is down-regulated 
in hypoxic conditions and specifically targets the 3’-
UTR region of HIF-1α [55]. Importantly, miR-199a-5p 
is down-regulated in a variety of malignancies including 
MM where its deregulation seems to be correlated with 
chromosomal aberrations [54, 56]. Consistent with these 
observations, we found a deregulated expression of miR-
199a-5p in myeloma cell lines. 
To investigate the potential role of miR-199a-5p in 
a pathological hypoxic context, we selected MM cell lines 
with lower levels of miR-199a-5p as compared to normal 
CD138+ cells. Using these cells, we found a reduction 
of miR-199a-5p expression in both cells exposed to 
hypoxic conditions and co-cultured with hypoxic BMSCs. 
Importantly, we showed that enforced expression of miR-
199a-5p significantly down-regulated the expression of 
HIF-1α in hypoxia-induced MM cells. In addition, we 
validated HIF-1α as a direct target of miR-199a-5p in 
myeloma cells. Accordingly, we found a strong reduction 
of Sirt1 expression, another miR-199a-5p predicted target 
required for HIF-1α accumulation [55, 57]. Interestingly, 
among the pro-angiogenic genes directly regulated by 
HIF-1α in MM cells, VEGF-A and IL-8 were strongly 
reduced after miR-199a-5p transfection, mainly in hypoxic 
conditions [11, 58, 59]. Consistent with these results, 
conditioned medium by miR-199a-5p-transfected hypoxic 
cells impaired IL-6 secretion by BMSCs. Consistent with 
the previously reported findings, the over-expression of 
miR-199a-5p in MM cells caused a decrease of bFGF 
expression, an important pro-angiogenic factor involved 
also in endothelial cell migration [60-63]. In fact, miR-
199a-5p transfected MM cells reduced the migration 
of endothelial cells. Notably, this effect was associated 
to a significantly decreased expression of cell-cell 
adhesion molecules in endothelial cells such as VCAM-
1 and ICAM-1. All together, these results suggest that 
restoration of miR-199a-5p has an important effect on 
myeloma-induced angiogenesis, acting on the production 
of pro-angiogenic factors by cells of the hypoxic 
microenvironment. 
The discoidin domain receptor-1 (DDR1) is a 
collagen tyrosine kinase over-expressed in several human 
cancers [64]. Several studies suggested a potential role 
of DDR1 in tumor cell migration and invasion, usually 
mediated by extracellular matrix degradation; in addition, 
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also DDR1 mRNA is predicted to be a potential target of 
miR-199a-5p [41]. In our study we found that repression 
of DDR1 protein upon enforced expression of miR-199a-
5p occurred together with a reduced cellular migration 
and reduced expression of the matrix metalloproteinase 
MMP2. In parallel, miR-199a-5p reduces the expression 
of CXCR4 in hypoxic conditions.
A recent report demonstrated that hypoxia reduces 
adhesion of MM cells to the BM stroma thus promoting 
dissemination [65]. In detail, the authors showed clearly 
that the mechanism by which hypoxia leads to de-adhesion 
of MM cells to the BM stroma is mediated by E-cadherin, 
one of the most important molecules in cell-cell adhesion 
[65]. In an hypoxic context, HIF-1α recognizes Snail gene 
promoter leading to a decrease of E-cadherin expression 
thus resulting in an impairment of cell-cell adhesion and 
promotion of motility, invasion and metastasis [66-68].
In our study, we first validated HIF-1α as direct 
target of miR-199a-5p and then we evaluated if miR-
199a-5p restoration in MM cells could have a role in the 
mechanism described above.
Hypoxic MM cells were transfected with miR-
199a-5p and, once HIF-1α was blocked, we observed 
the inhibition of Snail expression and higher levels of 
E-cadherin. 
We provide the first evidence, at our knowledge, 
that enforced expression of miR-199a-5p increases the 
percentage of hypoxic MM cells adherent to a monolayer 
of hypoxic BMSCs.
Taken together, these data suggest that i) miR199a-
5p has a role in regulating tumor dissemination induced by 
hypoxia, and that ii) miR-199a-5p modulates tumor cell 
migration, at least in part by targeting DDR1.
Furthermore, we demonstrated that the enforced 
expression of miR-199a-5p triggers anti-proliferative and 
pro-apoptotic effects in hypoxic MM cells. Importantly, 
all our observations translated in a significant in vivo 
activity of formulated synthetic miR-199a-5b delivery 
which add potential clinical significance to our study. 
Together with the significant inhibition of tumor growth, 
we indeed achieve a clear advantage in terms of mice 
survival. This result is of great interest since conventional 
MM xenografts are based on aggressive established cell 
lines which produce quickly growing tumors poorly 
vascularized providing therefore an in vivo suitable 
informative system predictive of therapeutic response. 
On the basis of this finding demonstrating a role 
for miR-199a-5p in MM angiogenic response and 
control of cell growth and survival, we investigated the 
molecular mechanism responsible of the miR-199a-5p 
downregulation in MM. It is well known that exposure 
to hypoxia elicits an adaptive response that also involves 
activation of the AKT pathway. It is well known that AKT 
enhances survival and anti-apoptotic gene expression 
acting also through miRNA-dependent mechanisms 
[69]. In particular, AKT induces downregulation of miR-
199a-5p, which is required for de-repression of Hif-1α 
[45, 55]. Here, we demonstrated that functional AKT1 
overexpression is sufficient in repressing miR-199a-5p 
expression while AKT1 depletion results in an increase 
of miR-199a-5p. Notably, miR-199a-5p induced also 
a reduction of total and phosphorylated AKT proteins 
expression. Although the precise molecular mechanisms 
underlying miR-199a-5p/Akt in MM needs to be fully 
elucidated, these results provide insights on miR-
199a-5p-Akt pathway cross-talk in MM indicating the 
occurrence of a regulatory negative loop where  miR-
199a-5p downregulates functional AKT which, in turn, 
represses miR-199-5p [70]. Recent findings indicate that 
miR-199a expression is finely regulated also by promoter 
methylation on both Chr1 and Chr19, where its gene 
is located. Indeed, studies in several cancer cell lines 
showed that both promoter regions on Chr1 and Chr19 
were hypermethylated [46, 71, 72]. Our findings indicate 
that treatment with demethylating agent can induce a 
restoration of miR-199a-5p expression in MM cells even 
if we can rule out, at least in our experimental conditions, 
a direct correlation with the methylation status of its 
promoter .
Treatments targeting the MM hypoxic niche are 
currently considered novel and promising therapeutics 
strategies. 
In summary, our results revealed that hypoxia 
down-regulates the expression of miR-199a-5p in MM 
via activation of AKT in order to allow the up regulation 
of HIF-1α and pro-angiogenic genes. Our investigation 
provides evidence on miR-199a-5p involvement in cell 
proliferation, migration and apoptosis and suggests 
a critical role for miR-199a-5p in the hypoxic tumor 
microenvironment. Taken together, these data support the 
development of miR-199a-5p mimics as a new potential 
therapeutic agents in the treatment of MM. The important 
interaction with AKT pathway opens new opportunities for 
combinatory therapeutical approaches which may result 
in a selective and highly efficient targeting of pathways 
crucially involved in the control of MM cell growth and 
survival in the huBMM.
MATERIALS AND METHODS
Cell Lines, Primary Cells and Drugs
MM cell lines were purchased from ATTC and 
grown in RPMI-1640 (Gibco, Life Technologies, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum (Lonza Group, Basel, Switzerland). HUVEC were 
obtained from Lonza (Clonetics, Verviers, Belgium) and 
grown in endothelial growth medium (EGM) according to 
supplier’s information.
Stromal HS-5 cells were purchased from ATCC 
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and cultured in Dulbecco’s modified Eagle’s medium, 
supplemented with 10% fetal bovine serum.
To induce hypoxia conditions, cells were placed in 
a modular incubator chamber (STEMCELL Technologies 
Inc., Vancouver, BC, Canada) and flushed for 5 minutes 
with a gas mixture of 5% CO2-95% N2; the final medium 
pO2 value was 2%. The chamber was then sealed and 
placed at 37°C in conventional cell incubator.
Alternately, cells were treated for 4 hours with 
100µM\L of the hypoxia-mimicking CoCl2 (Sigma-
Aldrich) which increased baseline levels of HIF-1α.
5-Azacytidine and PI3K inhibitor LY294002 
were purchased from Sigma Aldrich and Cell Signaling 
(Danvers, MA, USA), respectively. 
In vitro transfection of MM cells with synthetic 
mir-199a-5p
Synthetic pre-miRNAs were purchased from 
Ambion (miRNA mimic MC10893, Applied Biosystems). 
1x106 cells were electroporated with scrambled (miR-
NC) or synthetic pre-miR-199a-5p (miR-199a-5p) at a 
final concentration of 100nM, using Neon Transfection 
System (Invitrogen), with 1050 V, 30ms, 1 pulse.  Cell 
transfection efficiency was evaluated by flow cytometric 
analysis of FAMTM dye-labeled synthetic miRNA inhibitor 
(Invitrogen) transfection.
Quantitative real-time amplification of miRNAs 
and mRNAs.
Total cellular RNA was extracted using TRIzol 
Reagent (Invitrogen, Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer’s protocol. qRT–PCR 
was used to confirm the expression levels of mRNAs and 
miRNAs. 
The single-tube TaqMan miRNA (Assay ID 000498, 
Applied Biosystems, Life Technologies) was used to 
detect and quantify mature miR-199a-5p according to the 
manufacturer’s instructions, by the use of iQ5 multicolor 
detection system (Bio-Rad, Berkeley, CA, USA). miR-
199a-5p expression was normalized on RNU44 (Applied 
Biosystems, Assay Id 001094).
For mRNA detection, oligo-dT-primed cDNA 
was obtained using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and then used 
as template to quantify VEGF-A(hs00900054_m1), 
IL-8 (hs00174103_m1), IL-6(hs00985639_m1), 
FGFb (hs00266645_m1), MMP-2(hs01548727_m1), 
CXCR4(hs00237052_m1), SNAIL (hs00195591_m1), 
VCAM1(hs01003370_m1), ICAM1(hs00277001_m1), 
AKT1 (hs00920512_m1) levels by TaqMan assay 
(Applied Biosystems); normalization was performed 
with B-actin. Comparative real time polymerase chain 
reaction (RT–PCR) was performed in triplicate, including 
no-template controls. Relative expression was calculated 
using the comparative cross threshold (Ct) method.
Western blotting and antibodies
SDS-PAGE and Western Blotting (WB) were 
performed according to standard protocols [73]. Briefly, 
cells were lysed in lysis buffer containing 15mM Tris/
HCl pH7.5, 120mM NaCl, 25mM KCl, 1mM EDTA, 
0.5% Triton X100, Halt Protease Inhibitor Single-Use 
cocktail (100X, Thermo Scientific). Whole lysate (50µg 
per lane) were separated using 4-12% Novex Bis-Tris 
SDS-acrylamide gels (Invitrogen), electro-transferred on 
Nitrocellulose membranes (Bio-Rad), and immunoblotted 
with the appropriate antibodies. The antibodies against the 
following proteins were used for the procedure: Histone 
H3 (D1H2), HIF-1-α (#3716), E-cadherin (clone 24E10), 
, Phospho-Akt (Ser473), Akt (pan) (C67E7), Caspase-7 
(#9492), Caspase-3 (#9662), Cleaved PARP (Asp214; 
D64E10) were obtained from Cell Signaling (Beverly, 
MA). SIRT1  from Serotec and VEGF-A (MAB293) from 
R&D systems; α-Tubulin (C-20), MMP2 (2C1), DDR1 
(C-20), p21Cip1(sc-397), p27Kip1(sc-528), Bcl-2 (sc-7382), 
and all secondary antibodies were obtained from Santa 
Cruz Biotechnology (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). Chemiluminescence was detected 
using Pierce ECL Western Blotting Substrate (cat. 32109, 
Pierce, USA).
Nuclear fraction-enrichment
Cells were lysed in cytoplasm lysis buffer A 
(10mM HEPES pH 7.9, 10mM KCl, 0.2mM EDTA 
and 1mM DTT), containing protease inhibitors, 0.5mM 
phenylmethylsulfonylfluoride (PMSF) and 0.6% Nonidet 
P-40 (Sigma Chemical Co., St. Louis, MO, USA). Lysates 
were centrifuged at 10,000 r.p.m. for 10 min at 4°C, and 
the supernatants (cytoplasmic fractions) were split into 
aliquots and rapidly frozen. The nuclear pellet was washed 
in buffer A without Nonidet P-40 and finally resuspended 
in nuclear lysis buffer B (20mM HEPES pH 7.9, 0.4M 
NaCl, 2mM EDTA, 1mM DTT), containing protease 
inhibitors and 1mM PMSF (Sigma Chemical Co.). 
Samples were incubated on ice for 30 min and centrifuged 
at 13 000 r.p.m. for 10 min at 4 °C; the supernatants 
(nuclear fractions) were split into aliquots and rapidly 
frozen. The remaining pellets, containing DNA as well 
as proteins tightly associated with DNA, were washed 
in reticulocyte buffered buffer (RSB: 10mM NaCl, 
10mM Tris-HCl pH 7.5 and 1.5mM MgCl2) and finally 
resuspended in RSB and HCl 0.4N to obtain HCl-soluble 
proteins [74, 75]. The samples were incubated at least 1 
h at 4 °C and centrifuged at 10 000 r.p.m. for 20 min at 
4 °C. The acid-soluble proteins were recovered from the 
supernatants by precipitation with 10 volumes of acetone 
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at -20°C and centrifugation at 10,000 r.p.m. for 20 min 
at 4 °C. HCl-soluble proteins were finally resuspended in 
distilled water, split into aliquots and frozen.
Cell proliferation
For cell proliferation analysis, MM cells were 
plated in 6 well plates, electroporated with miR-199a-5p 
or miR-NC and then harvested, plated at 1,5-2,0x105/ml, 
and counted at 24 hours intervals using a Trypan Blue-
exclusion assay. 
Annexin v apoptosis assays
Annexin V apoptosis assays were performed using 
Annexin V-FITC kit (Biolegend, San Diego, CA, USA) 
according to manufacturer’s protocol. The stained cells 
were immediately analyzed on a FACScalibur flow 
cytometer (Becton Dickinson). The data were presented 
as the percentage of apoptotic cells.
Chemotaxis assay
Chemotaxis was determined using 8-u-pore filters 
for the Transwell migration assay (BD Biosciences), 
according to the manufacturer’s instructions. 
Briefly, OPM2 cells (1x105/well) transfected with 
either scrambled (miR-NC) or synthetic pre-miR-199a-5p 
(miR-199a-5p) were washed and resuspended in RPMI 
1640 medium supplemented with 1% FBS. Then cells 
were placed in the upper migration chambers, whereas 
the lower chamber contained RPMI 1640 medium 
supplemented with 10% FBS. After 5 hours of incubation 
at 37°C-5%CO2, cells migrated to the lower chambers 
were determined by a Trypan-Blue exclusion assay. Huvec 
(7x103 cells\well) were resuspended in serum free RPMI 
1640 medium supplemented with 0.1% BSA in transwell 
chemotaxis (BD Biosciences) above 8 um pore filters and 
exposed to conditioned medium from multiple myeloma 
cells transfected with either scrambled (miR-NC) or 
synthetic pre-miR-199a-5p (miR-199a-5p). 
Filters were removed after 6 hours, fixed in methanol 
and stained with Diff-Quick (Medion Diagnostics 
GmbH). Two independent experiments were carried out 
in triplicate; cells from five different fields were counted 
for each condition.
Adhesion assay
HS-5 stromal cells were grown to confluence in 
12-well plates and fixed with glutaraldehyde 0.0125% 
(Agar Scientific LTD). After fixation, cells were treated 
with 10 mM ethanolamine to block aldehydic groups and 
washed several times before plating MM cells.OPM2 cells 
(0.5x106 cells\well) transfected with either scrambled 
(miR-NC) or synthetic pre-miR-199a-5p (miR-199a-
5p) were added to each well and incubated for 4 hours 
at 37°C-5%CO2. Non adherent cells were washed and 
adhesion was detected by hematoxylin/eosin staining. 
Each test group was assayed in triplicate; five fields 
were counted for each condition.For cells cultured under 
hypoxic conditions, all procedures were performed in the 
hypoxic chamber (STEMCELL Technologies Inc.).
Luciferase reporter experiments
The 3’UTR of HIF-1α were cloned in pEZX-MT01 
vector and purchased from Genecopoeia. MM cells were 
electroporated as above described using 10µg of the 
firefly luciferase reporter; for each plate, 100 nM of the 
synthetic miR-199a-5p or miR-NC were used. Firefly and 
Renilla luciferase activities were measured consecutively 
using the dual-luciferase assay kit (Promega Corporation, 
Madison, WI, USA) 24 hours after transfection. 
Data are expressed as luminescence from firefly 
luciferase divided by luminescence from renilla luciferase.
Animals and in vivo models of human MM
Male CB-17 non-obese diabetic/severe combined 
immunodeficient (NOD.SCID) mice (6- to 8-weeks 
old; Harlan Laboratories, Inc., Indianapolis, IN, US) 
were housed and monitored in our Animal Research 
Facility. All experimental procedures and protocols had 
been approved by the Institutional Ethical Committee 
and conducted according to protocols approved by the 
National Directorate of Veterinary Services (Italy). In 
accordance with institutional guidelines, mice were 
sacrificed when their tumors reached 2 cm in diameter 
or in the event of paralysis or major compromise in their 
quality of life, to prevent unnecessary suffering. To obtain 
xenograft model of human MM, 5x106 NCI-H929 cells 
in 100 µL RPMI-1640 medium were subcutaneously 
injected into the interscapular area of NOD-SCID mice. 
Treatments were initiated after the detection of palpable 
tumors, (approximately 30 mm3), about 10 days following 
the injection of MM cells. The tumor sizes were measured 
as previously described [30] Mice were randomized 
into 2 groups and treated with synthetic miR-199a-5p 
mimics (Life Technologies) or scramble control (miR-
NC). Each dose contained 20 µg synthetic oligo, which 
equals 1mg/kg per mouse with an average weight of 20 g. 
Administration of miRNAs mimics was performed by the 
use of the neutral lipid emulsion (NLE) (MaxSuppressor 
in vivo RNA Lancer II, BIOO Scientific, Austin, TX) as 
previously described [76]. Treatments were performed 
intratumorally (i.t.) every three days for a total of six 
injections. 
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Elisa
VEGF-A levels secreted by MM cells were 
quantified by VEGF–enzyme-linked immunosorbent 
assays (Quantikine ELISA) (R&D Systems, Minneapolis, 
MN), according to the manufacturer’s recommendations. 
Briefly, OPM2 cells (1x106 cells\well) transfected 
with either scrambled (miR-NC) or synthetic pre-miR-
199a-5p (miR-199a-5p) were added to each well in RPMI 
supplemented with 1% FBS and cultured in both normoxic 
and hypoxic conditions. Supernatants were harvested after 
48 hours and analyzed.
Statistical analysis
The data were expressed as means±s.d. Differences 
were assessed by two tailed Student’s t-test using the Excel 
software. P value < 0.05 was considered to be statistically 
significant.
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